Overview
Level Zero Health develops a biosensor platform for remote, continuous hormone monitoring using a minimally invasive arm patch. The patch uses DNA-based biosensors and microneedles to measure hormones like progesterone, estrogen, cortisol, and testosterone in interstitial fluid and sends real-time data to a connected system. It differentiates itself by delivering continuous wearable hormone data with validated accuracy and by targeting B2B clinical workflows in IVF, menopause care, and TRT, with plans to pursue regulatory approvals. Its goal is to replace infrequent blood or urine tests with continuous data streams to support personalized care and later expand into consumer and pharmaceutical markets.
Work here?Claim your company
Simplify's take
What believers are saying
- Major IVF clinics signed $3 million in letters of intent, validating near-term demand.
- July 2026 SPRIND selection adds non-dilutive capital and German credibility for development.
- February 2025's $6.9 million pre-seed from Redalpine, HAX, and EF funds runway.
What critics are saying
- FDA and CE clearance still gate 2026 revenue; pre-seed cash cannot fund long approvals.
- No public human data yet; simulated 98% accuracy will face brutal clinical validation.
- Clair Health's $11.6 million June 2026 round intensifies competition in noninvasive hormone monitoring.
What makes Level Zero Health unique
- DNA-based microneedle patches measure progesterone, estrogen, cortisol, and testosterone continuously.
- Level Zero Health targets IVF clinics first, not consumers, with treatment-linked hormone data.
- Founders combine Palantir product execution, Philips sensor engineering, and hard-tech medical-device experience.
Help us improve and share your feedback! Did you find this helpful?